BEBT 503
Alternative Names: BEBT-503Latest Information Update: 29 Aug 2022
At a glance
- Originator Guangzhou BeBetter Medicine Technology
- Developer BeBetter Med
- Class Antihyperglycaemics; Hepatoprotectants
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 01 Aug 2022 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in Australia (PO) (NCT05391880)
- 01 Aug 2022 Phase-I clinical trials in Type 2 diabetes mellitus (In volunteers) in Australia (PO) (NCT05391880)
- 01 Jun 2022 Preclinical trials in Non-alcoholic steatohepatitis in China (PO) prior to June 2022 (BeBetter Med pipeline, June 2022)